Source: Annual Congress 2011 - Imaging in oncology and infectious diseases
Disease area: Thoracic oncology



Rating:

Share or cite this content

Citations should be made in the following way:
K. Zimmermann, S. Tönnies, D. Misch, C. Boch, N. Schoenfeld, G. J. Förster, J. Kollmeier, T. Bauer (Berlin, Germany). Staging with FDG-PET/CT influences stage-specific survival in non small cell lung cancer (NSCLC). Eur Respir J 2011; 38: Suppl. 55, 3660

Member's Comments

No comment yet.

Related content which might interest you: Extrathoracic 18-FDG-PET uptakes in non small cell lung cancer (NSCLC) preoperative staging Source: Eur Respir J 2007; 30: Suppl. 51, 430s Year: 2007 Prevalence of silent brain metastasis (BM) in the initial staging of non-small cell lung carcinoma (NSCLC) Source: Annual Congress 2011 - Imaging, functional evaluation and staging for lung cancer patients Year: 2011 Staging of lung cancer Source: Eur Respir Mon; 2009: 44: 150–168 Year: 2009 Utility of 18 FDG-PET scan in stage 1a non small cell lung cancer (NSCLC) Source: Annual Congress 2009 - Epidemiology and management of lung cancer Year: 2009 Quality indicators in lung cancer care-review of resection rates in early stage NSCLC (non small cell lung cancer) at King’s Source: International Congress 2018 – Lung cancer: risk factors, supportive measures and quality improvement Year: 2018 The influence of secondary infectious process on non-small cell lung cancer (NSCLC) patients survival Source: Eur Respir J 2007; 30: Suppl. 51, 280s Year: 2007 Analysis of survival and characteristics of patients with non-small cell lung carcinoma (NSCLC) stage IV depending on molecular markers Source: International Congress 2019 – Biology and prognosis of lung cancer Year: 2019 A novel biologic classification of non-small cell lung cancer Source: Annual Congress 2005 - New insights into prognosis in thoracic surgical oncology Year: 2005 Trends in drug costs and overall survival in patients diagnosed with metastatic non-small cell lung cancer (NSCLC) Source: International Congress 2019 – How to guide patients to reach a balance between costs and personal needs: quality indicators of effectiveness Year: 2019 Validation of the prognostic value of growth pattern classification in operated non-small cell lung cancer (NSCLC) Source: Annual Congress 2010 - Actual challenges in thoracic surgery Year: 2010 Preoperative FDG uptake on PET/CT predicts disease recurrence and survival in early stage non-small cell lung cancer (NSCLC) Source: International Congress 2016 – Clinical aspects of lung cancer Year: 2016 TTF-1 for prediction of response to chemotherapy in patients with locally advanced or metastatic small cell lung cancer (SCLC) Source: Annual Congress 2012 - Treatment of lung cancer Year: 2012 24h-blood profile gene expression biomarkers of the response to bevacizumab-erlotinib (BE) in advanced non-squamous non-small cell lung cancer (NSCLC) Source: International Congress 2016 – Therapeutic trials in lung cancer Year: 2016 Lung cancer Source: Respipedia Article Year: 2018 Analysis of the prognosis value of the mitochondrial activity in resected non-small cell lung cancer (NSCLC) Source: Annual Congress 2010 - Prognostic factors for lung cancer Year: 2010 Cancer recurrence in surgically treated non small cell lung cancer (NSCLC) Source: Eur Respir J 2006; 28: Suppl. 50, 755s Year: 2006 Prognostic factors in patients with resected pathologic stage I and II nonsmall cell lung cancer (NSCLC) Source: Eur Respir J 2002; 20: Suppl. 38, 269s Year: 2002 Staging and restaging in the era of multimodality treatment Source: Annual Congress 2006 - Integrative approaches for stage III non-small cell lung cancer Year: 2006 Role of EBUS-TBNA in the study of PD-L1 expression in patients with non-small cell lung cancer (NSCLC) Source: Virtual Congress 2020 – Endobronchial ultrasound: from rookie to pro Year: 2020 Prognostic factors in pathological stage IB nonsmall cell lung cancer greater than 3 cm Source: Eur Respir J 2010; 36: 1355-1361 Year: 2010